Statin use is associated with a reduced incidence of colorectal cancer: a colonoscopy-controlled case–control study

BMC Gastroenterology

Ian LP Beales¹  Jamie Sington²  Thomas Broughton¹ 

[1] Norwich Medical School, University of East Anglia, Norwich, NR4 7TJ, UK;Histopathology Department, Norfolk and Norwich University Hospital, Norwich, NR4 7UZ, UK

关键词: Colorectal adenocarcinoma;    Hydroxymethylglutaryl-CoA reductase inhibitors;    Chemoprevention;    Aspirin;   

Others  :  1113100
DOI  :  10.1186/1471-230X-12-36

 received in 2011-10-17, accepted in 2012-04-24,  发布年份 2012

【 摘 要 】

Background

The aetiology of colorectal cancer (CRC) remains elusive in the majority of cases. There is experimental evidence to show that HMG-CoA reductase inhibitors (statins) may inhibit proliferation and induce cause apoptosis in CRC cells and although some clinical studies have suggested that statins may protect against the development of CRC, this has not been a consistent finding. Therefore we have examined any potential protective effects of statins by comparing statin use in patients with colorectal cancer against a control group.

Methods

This was a case–control study examining statin use in symptomatic patients attending for diagnostic colonoscopy. Statin use was compared between patients with CRC and a control group, who had all had normal colonoscopy. Structured interviews and clinical records notes were used to determine drug exposure. Logistic regression was used to compare statin exposure and correct for confounding factors.

Results

There was a significant inverse association between previous statin use and a diagnosis of CRC (OR = 0.43 (95% confidence interval 0.25 – 0.80), p<0.01). This inverse association was stronger with higher statin doses (OR = 0.19 (0.07 – 0.47), p<0.01) and greater duration of statin use (statin use >years: OR = 0.18 (0.06 – 0.55), p<0.01).

Conclusions

Statins use was associated with a protective effect against the development of CRC. This effect is associated with a significant dose and duration response. These findings need to be repeated in other observational studies before an interventional study can be considered.

【 授权许可】

   
2012 Broughton et al.; licensee BioMed Central Ltd

【 参考文献 】

• [1]Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
• [2]Correa Lima MP, Gomes-da-Silva MH: Colorectal cancer: lifestyle and dietary factors. Nutr Hosp 2005, 20:235-241.
• [3]Washington MK: Colorectal carcinoma: selected issues in pathologic examination and staging and determination of prognostic factors. Arch Pathol Lab Med 2008, 132:1600-1607.
• [4]Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB, Hawk ET: Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006, 355:873-874.
• [5]Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005, 352:1071-1080.
• [6]Giouleme O, Diamantidis MD, Katsaros MG: Is diabetes a causal agent for colorectal cancer? Pathophysiological and molecular mechanisms. World J Gastroenterol 2011, 17:444-448.
• [7]Asano TK, McLeod RS: Non steroidal anti-inflammatory drugs (NSAID) and Aspirin for preventing colorectal adenomas and carcinomas. Cochrane Database Syst Rev 2004, CD004079.
• [8]Poynter JN, Gruber SB, Higgins PD, Almog R, Bonner JD, Rennert HS, Low M, Greenson JK, Rennert G: Statins and the risk of colorectal cancer. N Engl J Med 2005, 352:2184-2192.
• [9]Taylor ML, Wells BJ, Smolak MJ: Statins and cancer: a meta-analysis of case–control studies. Eur J Cancer Prev 2008, 17:259-268.
• [10]Friedman GD, Flick ED, Udaltsova N, Chan J, Quesenberry CP, Habel LA: Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf 2008, 17:27-36.
• [11]Lipkin SM, Chao EC, Moreno V, Rozek LS, Rennert H, Pinchev M, Dizon D, Rennert G, Kopelovich L, Gruber SB: Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer. Cancer Prev Res (Phila) 2010, 3:597-603.
• [12]Hachem C, Morgan R, Johnson M, Kuebeler M, El-Serag H: Statins and the risk of colorectal carcinoma: a nested case–control study in veterans with diabetes. Am J Gastroenterol 2009, 104:1241-1248.
• [13]Feleszko W, Jakobisiak M: Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin Cancer Res 2000, 6:1198-1199.
• [14]Ogunwobi OO, Beales IL: Statins Inhibit Proliferation and Induce Apoptosis in Barrett's Esophageal Adenocarcinoma Cells. Am J Gastroenterol 2008, 103:825-837.
• [15]Minoo P, Zlobec I, Peterson M, Terracciano L, Lugli A: Characterization of rectal, proximal and distal colon cancers based on clinicopathological, molecular and protein profiles. Int J Oncol 2010, 37:707-718.
• [16]Jalving M, Koornstra JJ, De Jong S, De Vries EG, Kleibeuker JH: Review article: the potential of combinational regimen with non-steroidal anti-inflammatory drugs in the chemoprevention of colorectal cancer. Aliment Pharmacol Ther 2005, 21:321-329.
• [17]Jacob EJ, Newton C, Thun M, Gapstur S: Long-term Use of Cholesterol-Lowering Drugs and Cancer. Incidence in a Large United States Cohort. Cancer Res 2011, 71:1763071.
• [18]Bardou M, Barkun A, Martel M: Effect of statin therapy on colorectal cancer. Gut 2010, 59:1572-1585.
• [19]Boudreau D, Yu O, Johnson J: Statin use and cancer risk: A comprehensive review. Expert Opin Drug Saf 2010, 9:603-621.
• [20]Shadman M, Newcomb PA, Hampton JM, Wernli KJ, Trentham-Dietz A: Non-steroidal anti-inflammatory drugs and statins in relation to colorectal cancer risk. World J Gastroenterol 2009, 15:2336-2339.
• [21]Singh H, Mahmud SM, Turner D, Xue L, Demers AA, Bernstein CN: Long-term use of statins and risk of colorectal cancer: a population-based study. Am J Gastroenterol 2009, 104:3015-3023.
• [22]Haukka J, Sankila R, Klaukka T, Lonnqvist J, Niskanen L, Tanskanen A, Wahlbeck K, Tiihonen J: Incidence of cancer and statin usage–record linkage study. Int J Cancer 2010, 126:279-284.
• [23]Coogan PF, Smith J, Rosenberg L: Statin use and risk of colorectal cancer. J Natl Cancer Inst 2007, 99:32-40.
• [24]Kaye JA, Jick H: Statin use and cancer risk in the General Practice Research Database. Br J Cancer 2004, 90:635-637.
• [25]Vinogradova Y, Hippisley-Cox J, Coupland C, Logan RF: Risk of colorectal cancer in patients prescribed statins, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 inhibitors: nested case–control study. Gastroenterology 2007, 133:393-402.
• [26]Simon M, Rosenberg C, Rodabough R, Greenland P, Ockene I, Roy H, Lan D, Cauley J, Khandekar J: Prospective analysis of association between use of statins or other lipid-lowering agents and colorectal cancer risk. Ann Epidemiol 2012, 22:17.
• [27]Morgan C, Lunt M, Bunn D, Scott DG, Symmons DP: Five-year outcome of a primary-care-based inception cohort of patients with inflammatory polyarthritis plus psoriasis. Rheumatology (Oxford) 2007, 46:1819-1823.
• [28]Strandberg TE, Pyorala K, Cool TJ, Wilhelmsen L, Faergeman O, Thorheirsoon R, et al.: Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 2004, 364:771-777.
• [29]Teraoka N, Mutoh M, Takasu S, Ueno T, Yamamoto M, Sugimura T, Wakabayashi K: Inhibition of intestinal polyp formation by pitavastatin, a HMG-CoA reductase inhibitor. Cancer Prev Res (Phila) 2011, 4:445-453.
• [30]Yasuda Y, Shimizu M, Shirakami Y, Sakai H, Kubota M, Hata K, Hirose Y, Tsurumi H, Tanaka T, Moriwaki H: Pitavastatin inhibits azoxymethane-induced colonic preneoplastic lesions in C57BL/KsJ-db/db obese mice. Cancer Sci 2010, 101:1701-1707.
• [31]Narisawa T, Fukaura Y, Terada K, Umezawa A, Tanida N, Yazawa K, Ishikawa C: Prevention of 1,2-dimethylhydrazine-induced colon tumorigenesis by HMG-CoA reductase inhibitors, pravastatin and simvastatin, in ICR mice. Carcinogenesis 1994, 15:2045-2048.
• [32]Siddiqui AA, Nazario H, Mahgoub A, Pandove S, Cipher D, Spechler SJ: The long-term use of statins is associated with a decreased incidence of adenomatous colon polyps. Digestion 2009, 79:17-22.
• [33]Parker-Ray N, Barakat J, Roy PK, White RE, Schrader RM, Hoffman RM: Statin use does not prevent recurrent adenomatous polyp formation in a VA population. Indian J Gastroenterol 2010, 29:106-1.
• [34]Wu JS, Fazio VW: Colon cancer. Dis Colon Rectum 2000, 43:1473-1486.
• [35]Lee J, Baba Y, Ng K, Giovannucci E, Fuchs C, Ogino S, Chan AT: Statin use and colorectal cancer risk according to molecular subtypes in two large prospective cohort studies. Cancer Prev Res (Phila) 2011.
• [36]Lee J, Lee I, Han B, Park JO, Jang J, Park C, Kang WK: Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations. J Natl Cancer Inst 2011, 103:674-688.
• [37]Goodwin JS, Singh A, Reddy N, Riall TS, Kuo YF: Overuse of screening colonoscopy in the Medicare population. Arch Int Med 2011, 171:1335-1341.
• [38]Chan AO, Jim MH, Lam KF, Morris JS, Siu DC, Tong T, Ng FH, Wong SY, Hui WM, Chan CK, Lai KC, Cheung TK, Chan P, Wong G, Yuen MF, Lau YK, Lee S, Szeto ML, Wong BC, Lam SK: Prevalence of colorectal neoplasm among patients with newly diagnosed coronary artery disease. JAMA 2007, 298:1412-1419.
• [39]Hippisley-Cox J, Coupland C: Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 2010, 340:c2197.
• [40]Decensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, Bonanni B, Gandini S: Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila) 2010, 3:1451-1461.
• [41]Agarwal B, Rao CV, Bhendwal S, Ramey WR, Shirin H, Reddy BS, Holt PR: Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac. Gastroenterology 1999, 117:838-847.
• [42]Reddy BS, Wang CX, Kong AN, Khor TO, Zheng X, Steele VE, Kopelovich L, Rao CV: Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats. Cancer Res 2006, 66:4542-4546.
• [43]Swamy MV, Patlolla JM, Steele VE, Kopelovich L, Reddy BS, Rao CV: Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice. Cancer Res 2006, 66:7370-7377.
• [44]Xiao H, Zhang Q, Lin Y, Reddy BS, Yang CS: Combination of atorvastatin and celecoxib synergistically induces cell cycle arrest and apoptosis in colon cancer cells. Int J Cancer 2008, 122:2115-2124.